PO: $ IV: $$

General Information

  • Use in Pneumonia and Acute otitis media should be limited due to high levels of resistance with common pathogens (e.g. Streptococcus pneumonia)
  • Cystic fibrosis, as an anti-inflammatory agent, Mycobacterium avium complex, Group A streptococci (GAS) pharyngitis, Pertussis, treatment and postexposure prophylaxis
  • Chlamydial urethritis, cervicitis and pelvic inflammatory disease, in patients ≥16 yrs

ODB funded (tablets, oral liquid)

Prolongation of QTc interval - Association with increased cardiovascular mortality in observational studies

Prolonged half life may contribute to macrolide resistance

  • Tablets can be given with or without food
  • Extended release suspension should be taken on an empty stomach (at least 1 hour before or 2 hours following a meal)
  • While less risk of interaction compared to other macrolides, several potential CYP450 interactions may occur; consult a pharmacist for for more details

    • Clearance of other drugs including tacrolimus, cyclosporine, and phenytoin may also be decreased
  • Avoid concurrent use with other drugs that prolong QTc

T 1/2: Infants and children 54.5 hours Excretion: Biliary (50% unchanged); urine (6-14% unchanged)